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SUMMARY
P-glycoprotein in the membranes of endothelial cells actively transports some drugs out of the brain.
The theoretical effect of P-glycoprotein mediated drug efflux on the cerebral distribution volumes of drugs 
was examined, with particular emphasis on anaesthetic-related drugs (often characterized by moderate to high
permeability across the blood brain barrier due to their lipophilicity and intermediate molecular weight). An analytical
equation for the cerebral distribution volume in the presence of the efflux was derived, and validated by modelling the
same system using differential equations.
The efflux was shown to lower both the membrane and intracellular drug concentrations in parallel, and to reduce
the time required for brain:blood equilibration. The net effect of the efflux was governed by the ratio of the 
P-glycoprotein drug clearance from the membrane (Pcl) and the permeability of the membrane (PS). It was therefore
a balance between the rate that a drug could be pumped out of the membrane by the efflux system, and the rate that
the drug leaked back in due to the permeability of the membrane for the drug. The effect of the efflux was therefore
more pronounced for drugs with membrane-limited cerebral kinetics (e.g. morphine), but was nevertheless significant
for drugs with more flow-limited kinetics (e.g fentanyl). The cerebral distribution volume was also influenced by the
free fraction in blood and the free fraction in the intracellular space in the conventional manner.
There are no theoretical limitations to the P-glycoprotein system influencing the cerebral distribution volume of
moderately lipophilic anaesthetic-related drugs. 
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P-glycoprotein (also known as the multidrug trans-
porter) is normally expressed in the epithelial cells of
the liver, kidney, intestine and the endothelial cells 
of the blood-brain barrier1. It consumes ATP and
actively removes compounds from the membrane of
cells directly into the adjacent lumen. P-glycoprotein
substrates are generally moderately lipophilic, basic
(or uncharged), and have a molecular weight (MW)
between approximately 250 and 1900 Da1. An
analogous protein of the same family (multi-drug
resistance protein, MRP) may serve a similar role
(amongst others) for lipophilic, acidic compounds2.
Functionally, P-glycoprotein-mediated efflux 
serves to limit exposure to xenobiotic compounds by
reducing their rate of oral absorption, increasing
their rate of excretion by the liver and kidney, and
reducing their entry into the brain. The latter organ is
of particular interest in the field of anaesthesia, as
some anaesthetics and analgesics (e.g. morphine3,
midazolam4, fentanyl5, methadone6) that have 
direct effects on the central nervous system are 
P-glycoprotein substrates.
The role of P-glycoprotein mediated drug efflux in
moderating the brain concentrations and central ner-
vous system (CNS) effects of drugs is still emerging,
but knowledge is advancing rapidly due to the ability
to “knock-out” (remove) the gene for this and related
proteins in mice, and to the development of specific
P-glycoprotein inhibitors. P-glycoprotein knockout
mice are apparently normal except for a considerably
enhanced sensitivity to some drugs1.  The analgesic
effect of morphine (via a hot plate method) was
shown to be enhanced approximately four-fold in
knockout mice, while that of methadone was substan-
tially increased and that of fentanyl was increased to
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a small extent6. The effects of pethidine and mor-
phine-6-glucuronide were unchanged. There is good
evidence that these analgesic changes are mediated
by changes in the brain concentrations of the drugs.
The brain concentrations of morphine have been
shown to be two- to five-fold higher when 
P-glycoprotein was absent or inhibited3,7,8.
These findings are consistent with P-glycoprotein
mediated drug efflux reducing the cerebral distribu-
tion volumes of substrate drugs. The accepted
explanation for the determinants of the cerebral dis-
tribution volume (Vbrn) is based on diffusion of the
free form of the drug across a blood-brain barrier,
which excludes bound (and ionised) forms of the
drug.  If the capillary volume of the brain is Vcap, and
the real intracellular volume of the brain is Vi, 





The free (unbound) fractions in plasma and the
intracellular space are represented by fu,p and fu,i
respectively. Although it is the free concentration of
drug in the brain that is thought to govern cerebral
drug effects, the total cerebral distribution volume of
anaesthetic-related drugs is important as it governs
the time required for the cerebral drug concentra-
tions to equilibrate with the drug concentration in
arterial blood. There is evidence that differences in
this equilibration time dictate some important clinical
properties of intravenous anaesthetics11 and opioids12.
The aim of this paper is to modify Equation 1 to
account for P-glycoprotein mediated drug efflux from
the brain. This is intended to provide insight into 
the determinants of the cerebral distribution volume
in the presence of such efflux, and to provide a
theoretical foundation for subsequent experimental
work in this area.
MATERIALS AND METHODS
Equation 1 is derived by equating the input and
output rates of drug transport for a model system as
shown in Figure 1. At steady state, these rates are
equal by definition. To add the effect of P-glycopro-
tein mediated efflux requires some modification of
this system, as shown in Figure 2. As P-glycoprotein
removes drug directly from the cell membrane1, it is
necessary for the model to represent the membrane
concentration of the drug. For both model systems,
the capillary, membrane and intracellular volumes
are assumed to be well mixed, and can therefore be
represented by compartments.
Venous Concentrations at Steady State
When the system shown in Figure 2 is at steady
state, it is evident that the venous concentration in
the capillary compartment (Cv) is equal to the arteri-
al concentration (Cart) entering the compartment:
Cv=Cart (2)
Intracellular Concentrations at Steady State
Furthermore, the intracellular drug concentration
(Ci) at steady state can be derived from equating the
rate that drug is entering the intracellular compart-
ment (ratein) with the rate that it is leaving the
compartment (rateout):
ratein=rateout (3)
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FIGURE 1: A traditional membrane-limited model of drug kinetics in an organ. The membrane barrier has no capacity to hold drug, and the
permeability of the membrane is given by the permeability-surface area coefficient PS, which has the units of volume per unit time. Drug
is delivered to the capillary volume at a rate given by the arterial concentration (Cart) multiplied by the organ blood flow (Q). Drug leaves
the organ in venous blood at a rate given by Cv.Q, where Cv is the venous drug concentration. The free fraction in plasma and the
intracellular space are given by fu,p and fu,i respectively.
If Cm is the concentration of the drug in the
membrane, Equation 3 becomes:
PS.fu,m.Cm=PS.fu,i.Ci (4)
where fu,i is the free fraction in the intracellular
space, while fu,m is the “free fraction” of the drug in
the cell membrane.  The meaning of fu,m will be dis-
cussed later. “PS” is the permeability of the mem-
brane (Figure 1), and is a term with the units of flow
(volume per unit time). It can be thought of as the
proportionality constant relating the total rate of
drug diffusion (mass per unit time) and the free drug





Membrane Concentrations at Steady State
As for the intracellular concentrations, the drug
concentration in the membrane of the system shown
in Figure 2 can be derived from equating the rate that
drug is entering the membrane (ratein) with the rate
that it is leaving (rateout). However, the rate of 
efflux of drug from the membrane by P-glycoprotein
(rateefflux) must also be accounted for. Again, the
sum of these fluxes will be equal at steady state.
ratein=rateout+rateefflux (6)
Expressing Equation 6 in terms of concentrations
and permeability terms (as was done for Eqn. 4):
PS.fu,p.Cv+PS.fu,i.Ci=2.PS.fu,m.Cm+rateefflux (7)





Special Cases of the General Equation
Equation 8 specifies the rate of P-glycoprotein
mediated efflux from the membrane in general terms.
If the efflux is mediated by a single population of
energy dependent carrier proteins, the rate of efflux





Vmax is the maximum rate of efflux possible, and
km is the free concentration at which half of the
maximum rate is achieved.  Equation 9 can be substi-
tuted into Equation 8, but solving for Cm gives
equations that are intractably large. However, by
considering the case where the Cm is much less than
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FIGURE 2: The model system shown in Figure 1 has been modified to account for P-glycoprotein mediated efflux from the cell membranes.
There are now distinct permeability terms for drug entering and leaving the membrane—algebraic manipulation will show that PS in this
system is equivalent to PS in the system shown in Figure 1. The drug concentration in the membrane can be represented by giving the
membrane a finite volume. Drug can be actively transported from the cell membrane at a rate indicated by the general term “rateefflux”,
which in specific cases is referred to as Pcl. The free fraction in the membrane is given by fu,m.
km (i.e. pseudo first order kinetics), the rate of efflux




Vmax/km is the apparent clearance of the drug 
from the membrane, and will be defined as the 
P-glycoprotein-mediated membrane clearance of the
drug (Pcl). It is the proportionality constant between
the rate of efflux and the free drug concentration in
the membrane. Substituting Eqn. 10 into Eqn. 8 and
rearranging to give Cm over Cv gives:
Cm 1 fu,p
= . (11)
Cv Pcl fu,m(1 +      
PS)
Effect of P-glycoprotein Efflux on Cerebral Distribution
Volume
For a given constant afferent arterial drug concen-
tration, Equations 2, 5 and 11 give the corresponding
concentrations in venous (capillary), intracellular and
membrane compartments at steady state. To calculate
the total apparent distribution volume of a drug in
the brain requires assigning true volumes to these
compartments. In a 70 kg man, the real volume of the
brain (Vreal) is approximately 1.3l and cerebral blood
flow is approximately 0.75 l/min13. The capillary
volume of the brain is approximately 4% of its total
volume14. The total lipid content of the brain is rela-
tively low, with an average value of 11% reported15.
In the present model, the simplifying assumption is
made that all this lipid separates the capillary and
intracellular spaces. The remaining 85% of the brain
is predominately water (78%) and protein (7%)15,
which will be attributed to the intracellular space.
Based on these values, the apparent volume of distri-
bution of the brain is the total amount of drug in the
brain (the sum of concentration and volume in each





Substituting equations 5 and 11 and simplifying
gives:
0.11 fu,p 0.85 fu,p
Vbrn ≈Vreal (0.04+             *       +             *        ) (13)Pcl fu,m Pcl fu,i(1+     ) (1+     )PS PS
where the term in brackets to the right of Vreal
corresponds to the brain:blood partition coefficient
of the drug, often abbreviated to R. (In equations 12
and 13, the alternative symbol for multiplication (*) is
used, to avoid confusion with decimal points.)
Independent Validation of Equations
To validate the analytical derivation of the equa-
tions derived above, the system shown in Figure 2 was
written as differential equations and solved using a
modelling program (Scientist for Windows, Version 2,
Micromath, Utah, U.S.A.). The equations used are
given in Appendix 1.
The venous (capillary), membrane and intra-
cellular concentrations at steady state resulting from
a constant arterial concentration entering the organ
were simulated. Common parameter values were
used for both the equations and the simulation, and
the predicted concentrations at each site were com-
pared. A discrepancy between the two could indicate
an error in either.
Properties of the Equations
The effects of P-glycoprotein clearance (Pcl) on 
the concentration of drug in the membrane and
intracellular compartments were examined using
Equations 5 and 11. The concentration ratio was
plotted against a range of values of P-glycoprotein
clearance (Pcl) over membrane permeability (PS).
The effect of free fraction in the capillary, mem-
brane and intracellular compartments on the cerebral
distribution volume was examined using Equation 13.
The free fraction in each compartment was in turn set
at values ranging between 0 and 1, while the free frac-
tions in the other compartments were set at 0.5. The
ratio of Pcl/PS was also set at 0, 1 and 10. The cerebral
distribution volume was calculated for each unique
set of parameter values and the resulting data were
plotted.
Sensitivity Analysis
The model based on differential equations was 
also used to simulate the effect of the extent of 
P-glycoprotein clearance (Pcl) and the permeability of
the blood brain barrier (PS) on the cerebral kinetics
of a hypothetical drug. The kinetics were summarized
by two terms—the equilibrium brain:blood partition
coefficient (R), and the time required for brain:
blood equilibration to be complete. The permeability
was set at three values relative to cerebral blood flow
(Q), which were representative of membrane limited
(PS=0.2.Q), partially membrane limited (PS=2.Q)
and flow-limited (PS=20.Q) cerebral kinetics.
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RESULTS
The solutions of the analytical equations and the
model based on differential equations were identical,
thereby independently confirming the validity of the
equations as a description of the model system shown
in Figure 2.
Equation 11 predicts that the steady state concen-
tration of the drug in the membrane is influenced by
the ratio of the P-glycoprotein clearance from the
membrane (Pcl) and the permeability of the mem-
brane (PS). As may be expected, the steady state
membrane concentration is thus a balance between
the rate that drug can be pumped out of the mem-
brane by the efflux system, and the rate that the drug
leaks back in due to the permeability of the mem-
brane for the drug. The influence of Pcl/PS on the
steady state drug concentrations in membrane and
intracellular fluid (expressed as a ratio of the afferent
arterial drug concentration) is shown in Figure 3. In
this example, a 50% reduction was achieved when 
the ratio was 1, and the concentration was approxi-
mately 10% of normal when the ratio was 10. The
asymptotic nature of the relationship thereafter pro-
duced only modest reductions in concentration for
large increases in the activity of the efflux system.
Reductions in the membrane drug concentration
produced parallel changes in the intracellular drug
concentrations, as governed by Equation 5. Thus, the
P-glycoprotein mediated efflux from the membrane
had a major effect on the total brain concentration of
a drug.
The effect of free fraction in each of the three
tissue compartments on cerebral distribution volume
is summarized in Figure 4. Decreasing free fraction in
the plasma produced linear reductions in cerebral
distribution volume, as also inherent in Equation 1.
Increasing the P-glycoprotein membrane clearance
(increasing Pcl/PS) reduced the slope of this line.
A novel contribution of the present work is the
influence of the free fraction in the membrane on the
cerebral distribution volume. Interestingly, this effect
was predicted to be minor, as the total lipid content
of the brain is relatively small, and this minimizes the
contribution of the membrane concentrations to the
total amount of drug in the brain.  As expected
however, the distribution volume was reduced in the
presence of membrane efflux.
The effect of altered intracellular free fraction 
was as predicted by Equation 1—as free fraction 
is lowered to less than that in plasma, there are dis-
proportionally larger increases in cerebral distri-
bution volume. Small changes in intracellular free
fraction for a drug that is highly bound in the intra-
cellular space can therefore produce large changes 
in cerebral distribution volume. Again, increasing 
the P-glycoprotein membrane clearance (increasing
Pcl/PS) reduced the magnitude of this effect. Indeed,
the overall trend is that a high P-glycoprotein mem-
brane clearance greatly reduced the sensitivity of the
cerebral distribution volume to the free fraction in
both plasma and intracellular fluid.
The results of the sensitivity analysis are sum-
marized in Table 1. Membrane and intracellular
concentrations were considered, but the data were
similar and only data for the intracellular concentra-
tions are shown for simplicity. This is consistent with
the earlier observation that the membrane and intra-
cellular concentrations change in parallel. Note that
in the absence of P-glycoprotein efflux, increasing 
the degree of membrane limitation dramatically
increases the time to equilibration, but the partition
coefficient is unchanged. Increased P-glycoprotein
clearance (Pcl) reduces both the brain:blood partition
coefficient, and the time to reach brain to blood
equilibration.
DISCUSSION
Methods for Measurement of Cerebral Distribution
Volumes
While there are a number of methods for measur-
ing the cerebral uptake of drugs, not all measure the
cerebral distribution volume. In particular, methods
based on rapid injection into the carotid artery (such
as the brain uptake index method16) measure the
acute extraction of drug across the brain which will be
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FIGURE 3: The effect of increasing the ratio of P-glycoprotein
membrane clearance (Pcl) over membrane permeability (PS). The
steady state drug concentration in membrane and intracellular
fluid are shown, which are equal for this case where the free
fraction in the membrane and intracellular space were the 
same. These concentrations are expressed as a ratio of the afferent
arterial concentration—the ratio is 1 in the absence of 
P-glycoprotein mediated efflux (Pcl/PS = 0).
determined by blood-brain barrier permeability
rather than steady-state distribution volume. In con-
trast, cerebral distribution volume can be inferred
from the time-course of the arteriovenous drug con-
centration difference across the brain, as has been
done using a chronically instrumented sheep prepara-
tion11,17. Furthermore, cerebral kinetics can be
inferred, with some assumptions, from the time-
course of cerebral drug effects and arterial drug
concentrations in some instances3.
Effect of P-glycoprotein Efflux on Cerebral
Distribution Volume
An important implication of Equation 11 is that the
net effect of P-glycoprotein clearance on the concen-
tration of drug in the membrane is a balance between
the rate at which drug is pumped out of the mem-
brane, and the rate that it leaks back through the
membrane due to the permeability of the membrane
for the drug. The net effect is therefore highly
dependent on the intrinsic permeability of the blood
brain barrier to a drug. This is illustrated in Table 1.
The case of membrane-limited kinetics shown in
Table 1 would be representative of drugs that cross
the blood brain barrier very slowly—e.g. the
glucuronides of morphine18. It was predicted that
relatively low rates of P-glycoprotein efflux (Pcl)
could produce substantial reductions in the brain
blood partition coefficient of these compounds, 
and this is supported by in vitro evidence that 
P-glycoprotein activity contributes to the blood:brain
barrier for morphine-6-glucuronide19. The partially
membrane-limited case in Table 1 would be repre-
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TABLE 1
The effect of the extent of membrane limitation in cerebral kinetics
(see text) and the effective clearance of drug from the blood brain
barrier by the P-glycoprotein system (Pcl in l/min) on 1) the steady
state brain:blood partition coefficient (R) and 2) the total time




Brain: blood partition coefficient
Pcl = 0 1 1 1
Pcl=1 0.13 0.6 0.94
Pcl=5 0.03 0.23 0.75
Time to brain: blood equilibrium (min)
Pcl = 0 490 102.5 65
Pcl=1 166 64.5 61
Pcl=5 63 32 48.5
Data refer to the intracellular concentrations of hypothetical
drugs for which the free fractions were fixed at the following
values: fu,p=0.5, fu,m=0.1 and fu,i=0.5. Cerebral blood flows and
the real volumes of the capillary, membrane and intracellular
spaces were also fixed at the values described in the text.
FIGURE 4: The effect of altering free fraction (fu) in plasma (top
panel), the membranes (middle panel) or intracellular space 
(bottom panel) on distribution volume in the brain as given by
Equation 13. The default free fraction for each site was 0.5. Data
are shown for the cases of Pcl/PS set at 0, 1 and 10.
sentative of morphine, based on unpublished data
(Upton et al) on its cerebral kinetics in sheep. The
predicted fourfold reduction in brain:blood partition
coefficient with the highest rate of P-glycoprotein
activity (Pcl=5) is in keeping with the two- to five-fold
reduction in brain concentrations and analgesia
reported for morphine3,7,8. Note that the brain: blood
equilibration time was also predicted to be reduced to
a similar extent.
The flow-limited case in Table 1 would be repre-
sentative of pethidine and alfentanil, which are
known to have flow-limited cerebral kinetics17. For
these drugs, it was predicted that increasing the 
P-glycoprotein efflux would produce modest reduc-
tions in both the partition coefficient and the time to
equilibration. This strategy would therefore be an
inefficient investment of metabolic energy.  It is in-
teresting to note that there is evidence that the
analgesic effects of pethidine are not moderated by 
P-glycoprotein6, while there have been no reports that
alfentanil is a P-glycoprotein substrate. Fentanyl is an
interesting case, as there is evidence that despite its
relatively high lipophilicity, it has partially membrane
limited kinetics in some organs20. The model would
therefore predict that the effect of P-glycoprotein
would be intermediate between the cases of
morphine and pethidine discussed above. This is 
supported by the observation that the analgesia
produced by fentanyl is increased in mice without 
P-glycoprotein, but to a lesser extent than for mor-
phine6. There is also data that has been interpreted as
active uptake of fentanyl into the brain (i.e. in the
opposite direction to the P-glycoprotein efflux)21.
Effect of Inhibition of P-glycoprotein
As a number of compounds are known to be
inhibitors of P-glycoprotein, it is worthwhile consider-
ing the clinical potential of such drugs to increase the
therapeutic index of anaesthetic and analgesic drugs
that are P-glycoprotein substrates. As these drugs 
act in the brain, inhibition of P-glycoprotein efflux
(lower value for Pcl/PS) would increase the brain con-
centrations expected for a given dose, allowing a
reduction in dose for the same clinical effect. Those
dose-dependent adverse effects (e.g. on some com-
ponents of the cardiovascular system) that are not
mediated by the drugs’ cerebral concentrations would
therefore also be reduced. For this effect to be useful,
the ideal inhibitor should have no adverse effects 
of its own. No doubt the clinical potential of this
strategy will emerge as more in vivo studies are done
in this area.
Effect of Lipophilicity and Molecular Weight on
Cerebral Distribution Volume
While molecular weight does not influence the
cerebral distribution volume in theory, it is known
that membrane permeability (PS) is inversely related
to MW to the power of 3 or 422. In practical terms,
drugs with a MW of greater than 700 Da diffuse so
slowly through the blood-brain barrier that they are
effectively excluded from the brain1. High MW
lipophilic drugs are problematic as they can have both
high concentrations and long turnover times in the
membrane, and have the potential to disrupt mem-
brane function. It is has been suggested that removal
of these compounds is an important role of the 
P-glycoprotein system22.
Lipophilicity affects two important but unrelated
aspects of cerebral drug distribution—membrane
permeability and cerebral distribution volume.
Membrane permeability (PS) is proportional to lipo-
philicity, and this dictates whether cerebral kinetics
are flow- or membrane-limited. Once permeability
becomes sufficiently high, the flow-limited cerebral
kinetics predominate and further increases in the
lipophilicity do not produce greater rates of blood:
brain equilibration. The upper rate of equilibration 
is then governed by cerebral blood flow and the
cerebral distribution volume.
The role of lipophilicity in determining cerebral
distribution volume is made clear by considering the
determinants of the free fraction of the drug in the
membrane (fu,m). In pure lipid, there are no protein
molecules, so the free fraction is not determined by
binding to macromolecules in the normal sense.
Rather, the free fraction is equivalent to the activity
rather than concentration of the drug in the lipid, and
will by definition be inversely related to the lipid : pH




Substituting Eqn. 14 into Eqn. 11 shows that, as
expected, highly lipophilic drugs (high P) can achieve
high relative concentrations directly in the mem-
branes and lipid components of the brain. However,
the present study suggests that because the total lipid
content of the brain is relatively low, the cerebral dis-
tribution volume (Vbrn) is relatively unaffected by
changes in lipophilicity alone (Eqn. 12).
In support of these relationships between lipo-
philicity and cerebral kinetics, it has been observed
that homologous series of barbiturates of increasing
lipophilicity are characterized by increasing mem-
brane permeability in their uptake into the brain23.
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However, unbound distribution volume in the brain
was little affected by changes in lipophilicity.
Furthermore, changes in lipophilicity were also
associated with concurrent changes in plasma protein
binding, which had a much greater effect on the
cerebral distribution volume. This may be the main
mechanism by which the lipophilicity of a drug affects
its distribution volume in the brain.
In conclusion, the system shown in Figure 2 is 
the simplest that accounts for the influence of 
P-glycoprotein on cerebral drug distribution, and its
properties should be understood for this reason. In
future work, this system will be compared with pub-
lished experimental data on the cerebral distribution
volumes of a number of anaesthetic-related drugs
measured in a chronically instrumented sheep
preparation. While the system may evolve as it is
compared with these data, the present analysis will
provide a framework on which to build the analysis.
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Appendix 1—Differential equations
The differential equations describing the system









Cv =drug concentration in capillary blood
Cm =drug concentration in lipid membranes
Ci =drug concentration in the intracellular space
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Parameters
Vcap=capillary blood volume
Vm =lipid volume of brain
Vi =intracellular volume of brain
fup =free fraction in blood
fum =free fraction in lipid membranes
fui =free fraction in intracellular space
PS =permeability of membrane barrier
Pcl =effective clearance of drug from the mem-
branes by P-glycoprotein.
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